Comparison of the activation kinetics of the M 3 acetylcholine receptor and a constitutively active mutant receptor in living cells

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 236-245

  Hoffmann, Carsten ^a   Nuber, Susanne ^a   Zabel, Ulrike ^a   Ziegler, Nicole ^a   Winkler, Christiane ^a   Hein, Peter ^a   Berlot, Catherine H ^b   Bünemann, Moritz ^a   Lohse, Martin J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b WEIS CENTER FOR RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATROPINE; CARBACHOL; CHOLINERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; M3 ACETYLCHOLINE RECEPTOR; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION;

ACETYLCHOLINE; ASPARAGINE; CARBACHOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; POINT MUTATION; PROTEIN BINDING; RECEPTOR, MUSCARINIC M3; TYROSINE;

EID: 84863890709     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.077578     Document Type: Article

References (53)

1. Adan RA (2006) Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system. Trends Pharmacol Sci 27:183-186.
2. Adan RA and Kas MJ (2003) Inverse agonism gains weight. Trends Pharmacol Sci 24:315-321.
3. q activation in living cells. BMC Biol 9:32.
4. Ahuja S and Smith SO (2009) Multiple switches in G protein-coupled receptor activation. Trends Pharmacol Sci 30:494-502.
5. Alvarez-Curto E, Prihandoko R, Tautermann CS, Zwier JM, Pediani JD, Lohse MJ, Hoffmann C, Tobin AB, and Milligan G (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol 80:1033-1046.
6. Azpiazu I and Gautam N (2004) A fluorescence resonance energy transfer-based sensor indicates that receptor access to a G protein is unrestricted in a living mammalian cell. J Biol Chem 279:27709-27718.
7. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neuroscience 25:366-428.
8. Bond RA and Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27:92-96.
9. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
10. Costa T and Cotecchia S (2005) Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol Sci 26:618-624.
11. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
12. Dowling MR, Willets JM, Budd DC, Charlton SJ, Nahorski SR, and Challiss RA (2006) A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J Pharmacol Exp Ther 317:1134-1142.
13. Ford DJ, Essex A, Spalding TA, Burstein ES, and Ellis J (2002) Homologous mutations near the junction of the sixth transmembrane domain and the third extracellular loop lead to constitutive activity and enhanced agonist affinity at all muscarinic receptor subtypes. J Pharmacol Exp Ther 300:810-817.
14. Goedhart J, van Weeren L, Adjobo-Hermans MJ, Elzenaar I, Hink MA, and Gadella TW Jr (2011) Quantitative co-expression of proteins at the single cell level - application to a multimeric FRET sensor. PLoS One 6:e27321.
15. Hein P, Frank M, Hoffmann C, Lohse MJ, and Bünemann M (2005) Dynamics of receptor/G protein coupling in living cells. EMBO J 24:4106-4114.
16. s activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem 281:33345-33351.
17. Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
18. Hoffmann C, Gaietta G, Bünemann M, Adams SR, Oberdorff-Maass S, Behr B, Vilardaga JP, Tsien RY, Ellisman MH, and Lohse MJ (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods 2:171-176.
19. Hoffmann C, Gaietta G, Zürn A, Adams SR, Terrillon S, Ellisman MH, Tsien RY, and Lohse MJ (2010) Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat Protoc 5:1666-1677.
20. Hoffmann C, Zürn A, Bünemann M, and Lohse MJ (2008) Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol 153 (Suppl 1):S358-S366.
21. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M, and Ernst OP (2009) ztiA G protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 34:540-552.
22. q-green fluorescent protein fusion in living cells. Association with the plasma membrane is disrupted by mutational activation and by elimination of palmitoylation sites, but not be activation mediated by receptors or AlF4. J Biol Chem 276:4227-4235.
23. + channels. J Gen Physiol 133:347-359.
24. Johnston CA and Siderovski DP (2007) Receptor-mediated activation of heterotrimeric G-proteins: current structural insights. Mol Pharmacol 72:219-230.
25. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
26. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
27. Li B, Scarselli M, Knudsen CD, Kim SK, Jacobson KA, McMillin SM, and Wess J (2007) Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods 4:169-174.
28. Lohse MJ, Nuber S, and Hoffmann C (2012) Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev 64:299-336.
29. Maier-Peuschel M, Frölich N, Dees C, Hommers LG, Hoffmann C, Nikolaev VO, and Lohse MJ (2010) A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation. J Biol Chem 285:8793-8800.
30. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
31. Nelson CP, Nahorski SR, and Challiss RA (2006) Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 316:279-288.
32. i-protein heterotrimer. J Biol Chem 281:24506-24511.
33. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, and Schwartz TW (2009) Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30:249-259.
34. Oldham WM and Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9:60-71.
35. Pauwels PJ and Wurch T (1998) Review: Amino acid domains involved in constitutive activation of G-protein-coupled receptors. Mol Neurobiol 17:109-135.
36. Rosenbaum DM, Rasmussen SG, and Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356-363.
37. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
38. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455:497-502.
39. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
40. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, and Leurs R (2007) Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47:53-87.
41. Spalding TA and Burstein ES (2006) Constitutive activity of muscarinic acetylcholine receptors. J Recept Signal Transduct Res 26:61-85.
42. Spalding TA, Burstein ES, Wells JW, and Brann MR (1997) Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 36:10109-10116.
43. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, and Schertler GF (2011) The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471:656-660.
44. Stauffer TP, Ahn S, and Meyer T (1998) Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. Curr Biol 8:343-346.
45. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
46. Tate CG and Schertler GF (2009) Engineering G protein-coupled receptors to facilitate their structure determination. Curr Opin Struct Biol 19:386-395.
47. Tummino PJ and Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492.
48. Várnai P and Balla T (2006) Live cell imaging of phosphoinositide dynamics with fluorescent protein domains. Biochim Biophys Acta 1761:957-967.
49. Vilardaga JP, Bünemann M, Feinstein TN, Lambert N, Nikolaev VO, Engelhardt S, Lohse MJ, and Hoffmann C (2009) GPCR and G proteins: drug efficacy and activation in live cells. Mol Endocrinol 23:590-599.
50. Vilardaga JP, Bünemann M, Krasel C, Castro M, and Lohse MJ (2003) Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol 21:807-812.
51. Vilardaga JP, Steinmeyer R, Harms GS, and Lohse MJ (2005) Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol 1:25-28.
52. 5-acetylcholine receptors. Bioorg Med Chem 19:1048-1054.
53. 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 75:534-541.